source
- GSK signs new agreement with China's Chimagen for trispecific T-cell engager targeting blood cancersGSK, the UK‑based pharmaceutical company, has entered into a fresh licensing agreement with Chinese biotech Chimagen Biosciences. The partnership focuses on a trispecific T‑cell engager designed fo…
- Summit and Akeso report ivonescimab extends lung cancer survival by eight months versus Keytruda in Phase 3 trialSummit Therapeutics and its partner Akeso said their experimental dual-target drug ivonescimab added about eight months of overall survival for patients with lung cancer compared with Merck's Keytr…